REGENXBIO Reports $90.1 Million Net Loss and Revenue Decline in Latest Quarter

REGENXBIO Inc. reported significant financial challenges in its latest quarterly filing, revealing a net loss of $90.1 million for the three months ended March 31, 2026, compared to a net income of $6.1 million during the same period in 2025. Total revenues plummeted to $6.4 million, a stark decline from $89.0 million in the prior year, primarily due to a substantial drop in license and royalty revenue, which fell from $87.0 million to $5.1 million. This decrease was largely attributed to the absence of a $70 million upfront license fee recognized in the first quarter of 2025 from the collaboration with Nippon Shinyaku, as well as a decline in royalties from Zolgensma and Itvisma, which decreased by $11.9 million.

Operating expenses also increased, totaling $89.8 million for the first quarter of 2026, up from $76.9 million in the previous year. The rise in expenses was driven by a $10 million settlement with GlaxoSmithKline related to sublicense fee obligations, alongside increased research and development costs associated with ongoing clinical trials. Research and development expenses rose to $57.3 million, reflecting heightened activity in pivotal trials for the company's lead product candidates, including ABBV-RGX-314 and RGX-202.

In terms of operational metrics, REGENXBIO's cash, cash equivalents, and marketable securities stood at $150.5 million as of March 31, 2026, a decrease from $240.9 million at the end of 2025. The company indicated that this capital is expected to fund operations into early 2027, although it raised concerns about its ability to continue as a going concern without additional financing. The company has incurred cumulative losses totaling $1.22 billion since its inception, underscoring the financial pressures it faces.

Strategically, REGENXBIO is focused on advancing its gene therapy pipeline, which includes collaborations with AbbVie and Nippon Shinyaku for the development of ABBV-RGX-314 and RGX-121, respectively. The company is also navigating regulatory challenges, including a Complete Response Letter from the FDA regarding RGX-121, which has prompted discussions with the agency about potential paths forward. Despite these hurdles, REGENXBIO remains committed to its gene therapy initiatives, with plans to pursue accelerated approval for RGX-202 and continue its clinical trials.

Looking ahead, REGENXBIO's management emphasized the need for additional capital to support ongoing development and commercialization efforts. The company is exploring various financing options, including potential equity offerings and collaborations, to bolster its financial position and ensure the successful advancement of its product candidates. The outlook remains uncertain, contingent on the successful development and regulatory approval of its therapies, as well as the ability to secure necessary funding.